On Apr. 23, 2021, following a thorough safety review, including two meetings of the CDCﾒs Advisory Committee on Immunization Practices, the FDA and the CDC determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

The FDA determined that the available data show that the vaccineﾒs known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.